Hosted on MSN6m
Biotech Stock Roundup: NMRA Plunges on Study Failure, HOTH, VIR Soar on Study Data & More
It was a busy week in the biotech sector, with many regulatory and pipeline updates. Neumora Therapeutics NMRA plummeted on ...
Neumora Therapeutics’ stock craters after trial of major depressive disorder fails to meet main goals
Neumora Therapeutics Inc.’s stock tumbled 80% Thursday, after the clinical-stage biotech said a late-stage trial of a ...
bovnews1d
Why Did Neumora Therapeutics Inc (NMRA) Soar? Key Factors Explained
Neumora Therapeutics Inc’s profitability metrics reveal financial health. The company currently boasts a gross margin of -74.98%. The profit margin, also known as the revenue ratio or gross profit ...
FierceBiotech7d
Neumora stumbles at start of phase 3 depression readout run, sending stock down 80%
Neumora Therapeutics’ big bet on a new era of neuroscience has delivered an age-old result. The first of three late-stage ...
Neumora Therapeutics price target lowered to $7 from $22 at BofA
BofA analyst Geoff Meacham lowered the firm’s price target on Neumora Therapeutics (NMRA) to $7 from $22 and keeps a Buy rating on the shares.
Neumora Therapeutics: Tanking On Disastrous MDD Data, Bounce Back Unlikely
Neumora Therapeutics' lead candidate, navacaprant, failed to meet primary and secondary endpoints in its Phase 3 KOASTAL-1 ...
Neumora Therapeutics Target of Unusually High Options Trading (NASDAQ:NMRA)
Neumora Therapeutics, Inc. (NASDAQ:NMRA – Get Free Report) saw some unusual options trading on Monday. Stock traders acquired ...
pharmaphorum7d
Neumora laid low by depression trial failure
In a statement, Neumora revealed that the KOASTAL-1 study missed its primary endpoint, with navacaprant failing to achieve a ...
Neumora drops as depression therapy fails in late-stage trial
Neumora Therapeutics (NMRA) crashed after its Phase 3 study for its lead asset navacaprant in major depressive disorder ...
Neumora Therapeutics (NASDAQ:NMRA) Downgraded to “Sector Perform” Rating by Royal Bank of Canada
Royal Bank of Canada cut shares of Neumora Therapeutics (NASDAQ:NMRA – Free Report) from an outperform rating to a sector ...
Buy Rating Maintained for Neumora Therapeutics Due to Promising MDD Trial Results and Strong Financial Position
Analyst Douglas Tsao from H.C. Wainwright reiterated a Buy rating on Neumora Therapeutics, Inc. (NMRA – Research Report) and keeping the price ...
Neumora Therapeutics Depression Drug Fails In First Of Three Pivotal Phase 3 Trials
Neumora Therapeutics, Inc. (NASDAQ:NMRA) stock traded lower after the company released data from the Phase 3 KOASTAL-1 Study ...